Geoff Meacham
Stock Analyst at Citigroup
(4.36)
# 362
Out of 5,182 analysts
297
Total ratings
59.79%
Success rate
13.59%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Buy | $156 → $165 | $138.60 | +19.05% | 10 | Apr 13, 2026 | |
| BIIB Biogen | Maintains: Neutral | $215 → $190 | $175.75 | +8.11% | 20 | Apr 13, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Buy | $14 → $16 | $9.45 | +69.31% | 2 | Mar 27, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $95 → $125 | $90.16 | +38.64% | 3 | Mar 24, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $120 → $125 | $115.48 | +8.24% | 12 | Mar 20, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $115 → $125 | $103.75 | +20.48% | 5 | Mar 19, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $145 → $130 | $101.79 | +27.71% | 3 | Mar 11, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $97 → $85 | $54.05 | +57.26% | 4 | Mar 11, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $575 → $585 | $434.15 | +34.75% | 7 | Mar 10, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $55 → $58 | $49.94 | +16.14% | 2 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $120 | $85.67 | +40.07% | 8 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $73.20 | +16.12% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $110 → $115 | $115.05 | -0.04% | 2 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $17.79 | +6.80% | 6 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $64 | $58.95 | +8.58% | 9 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $315 → $345 | $349.90 | -1.40% | 14 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $230 | $209.05 | +10.02% | 22 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $50 | $48.42 | +3.26% | 4 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $14.96 | +234.22% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $49 | $15.19 | +222.58% | 3 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $26 | $27.23 | -4.52% | 7 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $2.69 | +197.95% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $75 | $71.62 | +4.72% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $700 | $746.92 | -6.28% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $28 | $54.87 | -48.97% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $33.32 | +50.06% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $45.33 | +10.30% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $55.49 | +67.60% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $10.31 | +35.86% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $77.34 | -30.18% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $8.66 | -30.68% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $1.98 | -49.49% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $1.06 | +277.36% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $904.11 | +21.67% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $23.35 | -14.35% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $34.95 | -11.30% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $234.79 | -27.59% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $0.91 | +1,768.13% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $1.16 | +1,977.92% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $12.52 | -68.04% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $18.21 | +53.76% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.46 | +1,284.93% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $2.05 | +1,611.49% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.37 | +2,965.69% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.28 | +7,167.44% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $7.21 | +24.83% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $9.19 | +552.88% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $27.22 | -15.50% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $95.65 | -14.27% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $579.16 | -83.60% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $20.51 | +290.05% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $128.20 | +5.30% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.50 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $4.33 | +361.89% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $9.98 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $319.98 | -50.62% | 5 | Nov 8, 2017 |
Gilead Sciences
Apr 13, 2026
Maintains: Buy
Price Target: $156 → $165
Current: $138.60
Upside: +19.05%
Biogen
Apr 13, 2026
Maintains: Neutral
Price Target: $215 → $190
Current: $175.75
Upside: +8.11%
MeiraGTx Holdings
Mar 27, 2026
Maintains: Buy
Price Target: $14 → $16
Current: $9.45
Upside: +69.31%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $95 → $125
Current: $90.16
Upside: +38.64%
Merck & Co.
Mar 20, 2026
Maintains: Neutral
Price Target: $120 → $125
Current: $115.48
Upside: +8.24%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Buy
Price Target: $115 → $125
Current: $103.75
Upside: +20.48%
BioNTech SE
Mar 11, 2026
Maintains: Buy
Price Target: $145 → $130
Current: $101.79
Upside: +27.71%
BioMarin Pharmaceutical
Mar 11, 2026
Maintains: Buy
Price Target: $97 → $85
Current: $54.05
Upside: +57.26%
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $575 → $585
Current: $434.15
Upside: +34.75%
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $55 → $58
Current: $49.94
Upside: +16.14%
Mar 2, 2026
Maintains: Buy
Price Target: $110 → $120
Current: $85.67
Upside: +40.07%
Mar 2, 2026
Initiates: Buy
Price Target: $85
Current: $73.20
Upside: +16.12%
Feb 24, 2026
Downgrades: Neutral
Price Target: $110 → $115
Current: $115.05
Upside: -0.04%
Feb 20, 2026
Maintains: Buy
Price Target: $15 → $19
Current: $17.79
Upside: +6.80%
Feb 6, 2026
Maintains: Neutral
Price Target: $60 → $64
Current: $58.95
Upside: +8.58%
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $345
Current: $349.90
Upside: -1.40%
Jan 27, 2026
Maintains: Neutral
Price Target: $235 → $230
Current: $209.05
Upside: +10.02%
Jan 27, 2026
Maintains: Buy
Price Target: $48 → $50
Current: $48.42
Upside: +3.26%
Jan 9, 2026
Initiates: Buy
Price Target: $50
Current: $14.96
Upside: +234.22%
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $15.19
Upside: +222.58%
Dec 2, 2025
Reinstates: Neutral
Price Target: $26
Current: $27.23
Upside: -4.52%
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.69
Upside: +197.95%
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $71.62
Upside: +4.72%
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $746.92
Upside: -6.28%
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $54.87
Upside: -48.97%
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $33.32
Upside: +50.06%
Oct 17, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $45.33
Upside: +10.30%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $55.49
Upside: +67.60%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $10.31
Upside: +35.86%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $77.34
Upside: -30.18%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $8.66
Upside: -30.68%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $1.98
Upside: -49.49%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $1.06
Upside: +277.36%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $904.11
Upside: +21.67%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $23.35
Upside: -14.35%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $34.95
Upside: -11.30%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $234.79
Upside: -27.59%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $0.91
Upside: +1,768.13%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $1.16
Upside: +1,977.92%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $12.52
Upside: -68.04%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $18.21
Upside: +53.76%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $2.46
Upside: +1,284.93%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $2.05
Upside: +1,611.49%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.37
Upside: +2,965.69%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.28
Upside: +7,167.44%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $7.21
Upside: +24.83%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $9.19
Upside: +552.88%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $27.22
Upside: -15.50%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $95.65
Upside: -14.27%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $579.16
Upside: -83.60%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $20.51
Upside: +290.05%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $128.20
Upside: +5.30%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $10.50
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $4.33
Upside: +361.89%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.98
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $319.98
Upside: -50.62%